<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02974426</url>
  </required_header>
  <id_info>
    <org_study_id>DLY201619</org_study_id>
    <nct_id>NCT02974426</nct_id>
  </id_info>
  <brief_title>To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with&#xD;
      histologically confirmed N2 disease are a heterogeneous population. After complete resection&#xD;
      and postoperative chemotherapy (POCT), 20%-40% of cases have a risk of locoregional&#xD;
      recurrence (LRR). Postoperative radiation therapy (PORT) should be an integral component of&#xD;
      the multidisciplinary treatment for patients with stage IIIA(N2) disease. Postoperative&#xD;
      Radiotherapy (PORT)-first strategy may have an advantage of the early administration of&#xD;
      locoregional therapy to the mediastinum, in which the tumor burden is presumed to be higher&#xD;
      than that of systematic micrometastases. It is not yet known for subsets with specific&#xD;
      prognostic factors that confer higher LRR risks, what is the optimal timing of PORT and how&#xD;
      to integrate with POCT (in a sequential fashion or concurrent fashion) when PORT is&#xD;
      considered for patients with completely resected stage IIIA(N2) NSCLC.&#xD;
&#xD;
      Purpose: This randomized phase III trial is studying the optimal timing of PORT to evaluate&#xD;
      whether the PORT-first strategy (PORT administered first with concurrent or subsequent POCT)&#xD;
      may be more effective than the PORT-last strategy (PORT administered sequentially following&#xD;
      POCT) in treating high risk of LRR patients with completely resected pathologic stage&#xD;
      IIIA(N2) NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        1. Primary&#xD;
&#xD;
           - Investigate the optimal timing of PORT for completely resected pathologic stage&#xD;
           IIIa(N2) NSCLC by comparing the disease-free survival of patients with high risk of LRR&#xD;
           treated with PORT-first vs PORT-last strategy.&#xD;
&#xD;
        2. Secondary&#xD;
&#xD;
             -  Determine the overall survival of patients treated with these regimens.&#xD;
&#xD;
             -  Compare the locoregional recurrence-free survival in patients treated with these&#xD;
                regimens.&#xD;
&#xD;
             -  Compare the distant metastasis-free survival in patients treated with these&#xD;
                regimens.&#xD;
&#xD;
             -  Determine patterns of failure in patients treated with these regimens.&#xD;
&#xD;
             -  Determine the toxicity, in particular cardiac and pulmonary toxicity, of these&#xD;
                regimens in these patients.&#xD;
&#xD;
             -  Determine the prediction models for locoregional recurrence and brain metastasis&#xD;
                based on the clinical, pathological, radiological, genetic, tumor&#xD;
                microenvironmental and immunological data.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized study. The clinical risk prediction model for LRR&#xD;
      has been established based on our large institutional database. On multivariate analysis,&#xD;
      heavy cigarette smoking history, cN2 status, and number of involved lymph nodes&gt;4 were&#xD;
      independently significant factors predicting high risk of LRR. The Prognostic Index (PI)&#xD;
      equation was built including the three categorical variables and coefficients based on their&#xD;
      level of significance: PI＝(0.9×smoking history)＋(0.5×clinical N status)＋(0.8×number of&#xD;
      involved lymph nodes). Patients with the PI score≥3.5 were considered as high risk of LRR.&#xD;
&#xD;
      Patients are stratified according to participating center, EGFR mutation status (EGFR 19del&#xD;
      or 21L858R mutations vs others), and use of pretreatment positron emission tomography scans&#xD;
      (yes vs no). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (PORT-first strategy): Concurrent chemoradiotherapy + sequential POCT or PORT +&#xD;
           sequential POCT Participants in the Arm I will receive PORT at the first day of therapy.&#xD;
           For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently&#xD;
           with POCT (two cycles of chemotherapy given during radiotherapy); then continue to give&#xD;
           two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be&#xD;
           administered first followed by subsequent four cycles of sequential POCT.&#xD;
&#xD;
        -  Arm II (PORT-last strategy): Four cycles of POCT + sequential PORT Participants in the&#xD;
           Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential&#xD;
           adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks)&#xD;
           will be administered.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1094 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional recurrence-free survival (LRFS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival (DMFS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse event</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1094</enrollment>
  <condition>Non-small Cell Lung Cancer Stage IIIA</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Arm I (PORT-first strategy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (PORT-last strategy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PORT-first</intervention_name>
    <description>PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.</description>
    <arm_group_label>Arm I (PORT-first strategy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PORT-last</intervention_name>
    <description>PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.</description>
    <arm_group_label>Arm II (PORT-last strategy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)</intervention_name>
    <description>Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma</description>
    <arm_group_label>Arm I (PORT-first strategy)</arm_group_label>
    <arm_group_label>Arm II (PORT-last strategy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 18 years to 75 years;&#xD;
&#xD;
          -  Complete resection through a surgical procedure of lobectomy, sleeve lobectomy or&#xD;
             bilobectomy with microscopically tumor-free resection margins and margin-negative&#xD;
             resection of all gross disease; Has undergone systematic nodal assessment (lymph node&#xD;
             dissection or sampling with a minimum of three N2 stations sampled or completely&#xD;
             dissected, one of which must be the subcarinal station);&#xD;
&#xD;
          -  Histologically proven lung adenocarcinoma or squamous cell lung carcinoma of stage&#xD;
             pT1-3N2M0 (according to the TNM classification in the Union for International Cancer&#xD;
             Control (UICC) 7th ed.);&#xD;
&#xD;
          -  Determined as the postoperative high risk of locoregional recurrence;&#xD;
&#xD;
          -  No documented metastases (M1) and/or invasion (T4) by the pretreatment examination or&#xD;
             at the time of surgery;&#xD;
&#xD;
          -  No prior neoadjuvant therapy (chemotherapy and/or RT);&#xD;
&#xD;
          -  No prior adjuvant therapy (chemotherapy and/or RT);&#xD;
&#xD;
          -  No severe perioperative complications and expected postoperative lifespan ≥4 months;&#xD;
&#xD;
          -  ECOG Performance Status 0-1;&#xD;
&#xD;
          -  Voluntarily participated in this study and signed the informed consent form by himself&#xD;
             or his agent. Had good compliance with the study procedures, and can cooperate with&#xD;
             the relevant examination, treatment and follow-up;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed large cell carcinoma, adenosquamous carcinoma, sarcomatoid&#xD;
             carcinomas, neuroendocrine tumors (small cell carcinoma, large cell neuroendocrine&#xD;
             carcinoma, carcinoid tumors, etc.), salivary-gland type tumors, adenomas, papillomas,&#xD;
             or other and unclassified carcinomas;&#xD;
&#xD;
          -  Patients undergoing pneumonectomy;&#xD;
&#xD;
          -  Diagnosed with other prior or concurrent malignancies (neoplasm) except for basal cell&#xD;
             carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years;&#xD;
&#xD;
          -  Patients with severe postoperative complications; and time to beginning of the&#xD;
             adjuvant therapy has been more than 2 months from the date of surgery;&#xD;
&#xD;
          -  Patients with any severe or uncontrolled systematic disease including severe&#xD;
             cardiovascular, liver, kidney, hematopoietic, metabolic disease, or uncontrolled&#xD;
             active infection that would preclude study participation;&#xD;
&#xD;
          -  Patients with positive mental disorder that would preclude study participation;&#xD;
&#xD;
          -  Contradictory to chest radiotherapy;&#xD;
&#xD;
          -  Pregnant or nursing women;&#xD;
&#xD;
          -  Concurrent other anti-cancer treatment;&#xD;
&#xD;
          -  Prior preoperative Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors&#xD;
             (EGFR-TKIs) treatment or other targeted therapy;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolong Fu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Fu, MD</last_name>
    <phone>862122200000</phone>
    <phone_ext>3609</phone_ext>
    <email>xlfu1964@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen Feng, MD</last_name>
    <phone>8622200000</phone>
    <phone_ext>3609</phone_ext>
    <email>fengwen412@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolong Fu, PhD</last_name>
      <phone>+862122200000</phone>
      <phone_ext>3602</phone_ext>
      <email>xlfu1964@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>NSCLC Meta-analyses Collaborative Group; Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010 Apr 10;375(9722):1267-77. doi: 10.1016/S0140-6736(10)60059-1. Epub 2010 Mar 24.</citation>
    <PMID>20338627</PMID>
  </reference>
  <reference>
    <citation>Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, Pignon JP, Le Pechoux C; PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016 Oct 11;10(10):CD002142. doi: 10.1002/14651858.CD002142.pub4.</citation>
    <PMID>27727451</PMID>
  </reference>
  <reference>
    <citation>Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006 Jul 1;24(19):2998-3006. doi: 10.1200/JCO.2005.04.6110. Epub 2006 Jun 12.</citation>
    <PMID>16769986</PMID>
  </reference>
  <reference>
    <citation>Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA; Adjuvant Navelbine International Trialist Association. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701. doi: 10.1016/j.ijrobp.2008.01.044. Epub 2008 Apr 24.</citation>
    <PMID>18439766</PMID>
  </reference>
  <reference>
    <citation>Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol. 2015 Mar 10;33(8):870-6. doi: 10.1200/JCO.2014.58.5380. Epub 2015 Feb 9.</citation>
    <PMID>25667283</PMID>
  </reference>
  <reference>
    <citation>Billiet C, Decaluwe H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K, De Leyn P, De Ruysscher D. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. Radiother Oncol. 2014 Jan;110(1):3-8. doi: 10.1016/j.radonc.2013.08.011. Epub 2013 Oct 4. Erratum In: Radiother Oncol. 2014 Nov;113(2):300-1.</citation>
    <PMID>24100149</PMID>
  </reference>
  <reference>
    <citation>Feng W, Fu XL, Cai XW, Yang HJ, Wu KL, Fan M, Xiang JQ, Zhang YW, Chen HQ. Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1100-7. doi: 10.1016/j.ijrobp.2013.12.048. Epub 2014 Feb 11.</citation>
    <PMID>24529715</PMID>
  </reference>
  <reference>
    <citation>Feng W, Zhang Q, Fu XL, Cai XW, Zhu ZF, Yang HJ, Xiang JQ, Zhang YW, Chen HQ. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer. 2015 May 2;15:348. doi: 10.1186/s12885-015-1326-6.</citation>
    <PMID>25934006</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 20, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xiaolong Fu</investigator_full_name>
    <investigator_title>Director, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02974426
org study id: DLY201619
nct id: NCT02974426
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with
      histologically confirmed N2 disease are a heterogeneous population. After complete resection
      and postoperative chemotherapy (POCT), 20%-40% of cases have a risk of locoregional
      recurrence (LRR). Postoperative radiation therapy (PORT) should be an integral component of
      the multidisciplinary treatment for patients with stage IIIA(N2) disease. Postoperative
      Radiotherapy (PORT)-first strategy may have an advantage of the early administration of
      locoregional therapy to the mediastinum, in which the tumor burden is presumed to be higher
      than that of systematic micrometastases. It is not yet known for subsets with specific
      prognostic factors that confer higher LRR risks, what is the optimal timing of PORT and how
      to integrate with POCT (in a sequential fashion or concurrent fashion) when PORT is
      considered for patients with completely resected stage IIIA(N2) NSCLC.

      Purpose: This randomized phase III trial is studying the optimal timing of PORT to evaluate
      whether the PORT-first strategy (PORT administered first with concurrent or subsequent POCT)
      may be more effective than the PORT-last strategy (PORT administered sequentially following
      POCT) in treating high risk of LRR patients with completely resected pathologic stage
      IIIA(N2) NSCLC.
OBJECTIVES:

        1. Primary

           - Investigate the optimal timing of PORT for completely resected pathologic stage
           IIIa(N2) NSCLC by comparing the disease-free survival of patients with high risk of LRR
           treated with PORT-first vs PORT-last strategy.

        2. Secondary

             -  Determine the overall survival of patients treated with these regimens.

             -  Compare the locoregional recurrence-free survival in patients treated with these
                regimens.

             -  Compare the distant metastasis-free survival in patients treated with these
                regimens.

             -  Determine patterns of failure in patients treated with these regimens.

             -  Determine the toxicity, in particular cardiac and pulmonary toxicity, of these
                regimens in these patients.

             -  Determine the prediction models for locoregional recurrence and brain metastasis
                based on the clinical, pathological, radiological, genetic, tumor
                microenvironmental and immunological data.

      OUTLINE: This is a multicenter, randomized study. The clinical risk prediction model for LRR
      has been established based on our large institutional database. On multivariate analysis,
      heavy cigarette smoking history, cN2 status, and number of involved lymph nodes>4 were
      independently significant factors predicting high risk of LRR. The Prognostic Index (PI)
      equation was built including the three categorical variables and coefficients based on their
      level of significance: PI＝(0.9×smoking history)＋(0.5×clinical N status)＋(0.8×number of
      involved lymph nodes). Patients with the PI score≥3.5 were considered as high risk of LRR.

      Patients are stratified according to participating center, EGFR mutation status (EGFR 19del
      or 21L858R mutations vs others), and use of pretreatment positron emission tomography scans
      (yes vs no). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (PORT-first strategy): Concurrent chemoradiotherapy + sequential POCT or PORT +
           sequential POCT Participants in the Arm I will receive PORT at the first day of therapy.
           For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently
           with POCT (two cycles of chemotherapy given during radiotherapy); then continue to give
           two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be
           administered first followed by subsequent four cycles of sequential POCT.

        -  Arm II (PORT-last strategy): Four cycles of POCT + sequential PORT Participants in the
           Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential
           adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks)
           will be administered.

      PROJECTED ACCRUAL: A total of 1094 patients will be accrued for this study.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Disease-free survival (DFS)
time frame: 4 years
measure: Overall survival (OS)
time frame: 4 years
measure: Locoregional recurrence-free survival (LRFS)
time frame: 4 years
measure: Distant metastasis-free survival (DMFS)
time frame: 4 years
measure: Treatment-related adverse event
time frame: 1 year
description: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
arm group label: Arm I (PORT-first strategy)
arm group type: Experimental
description: Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
arm group label: Arm II (PORT-last strategy)
arm group type: Active Comparator
description: Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
intervention type: Radiation
intervention name: PORT-first
description: PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
arm group label: Arm I (PORT-first strategy)
intervention type: Radiation
intervention name: PORT-last
description: PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
arm group label: Arm II (PORT-last strategy)
intervention type: Drug
intervention name: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
arm group label: Arm I (PORT-first strategy)
arm group label: Arm II (PORT-last strategy)
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Xiaolong Fu, MD
role: Principal Investigator
affiliation: Shanghai Chest Hospital
last name: Xiaolong Fu, MD
phone: 862122200000
phone ext: 3609
email: xlfu1964@126.com
last name: Wen Feng, MD
phone: 8622200000
phone ext: 3609
email: fengwen412@126.com
facility: 
status: Recruiting
contact: 
country: China
citation: NSCLC Meta-analyses Collaborative Group; Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010 Apr 10;375(9722):1267-77. doi: 10.1016/S0140-6736(10)60059-1. Epub 2010 Mar 24.
PMID: 20338627
citation: Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, Pignon JP, Le Pechoux C; PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2016 Oct 11;10(10):CD002142. doi: 10.1002/14651858.CD002142.pub4.
PMID: 27727451
citation: Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006 Jul 1;24(19):2998-3006. doi: 10.1200/JCO.2005.04.6110. Epub 2006 Jun 12.
PMID: 16769986
citation: Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA; Adjuvant Navelbine International Trialist Association. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701. doi: 10.1016/j.ijrobp.2008.01.044. Epub 2008 Apr 24.
PMID: 18439766
citation: Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol. 2015 Mar 10;33(8):870-6. doi: 10.1200/JCO.2014.58.5380. Epub 2015 Feb 9.
PMID: 25667283
citation: Billiet C, Decaluwe H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K, De Leyn P, De Ruysscher D. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. Radiother Oncol. 2014 Jan;110(1):3-8. doi: 10.1016/j.radonc.2013.08.011. Epub 2013 Oct 4. Erratum In: Radiother Oncol. 2014 Nov;113(2):300-1.
PMID: 24100149
citation: Feng W, Fu XL, Cai XW, Yang HJ, Wu KL, Fan M, Xiang JQ, Zhang YW, Chen HQ. Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1100-7. doi: 10.1016/j.ijrobp.2013.12.048. Epub 2014 Feb 11.
PMID: 24529715
citation: Feng W, Zhang Q, Fu XL, Cai XW, Zhu ZF, Yang HJ, Xiang JQ, Zhang YW, Chen HQ. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer. 2015 May 2;15:348. doi: 10.1186/s12885-015-1326-6.
PMID: 25934006
responsible party type: Principal Investigator
investigator affiliation: Shanghai Chest Hospital
investigator full name: Xiaolong Fu
investigator title: Director, Department of Radiation Oncology
mesh term: Lung Neoplasms
mesh term: Carcinoma, Non-Small-Cell Lung
mesh term: Cisplatin
mesh term: Carboplatin
mesh term: Pemetrexed
mesh term: Vinorelbine
sharing ipd: No